Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.45 |
| ▸ | WNT3A | P56704 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987669 | 0.85 | NFE2L2 (0.43) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| SCHEMBL5325529 | 0.83 | CTNNB1 (0.46) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| SCHEMBL14208205 | 0.83 | ALDH1A1 (0.42) | NFE2L2GAAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL286833 | 0.83 | KDM4E (0.55) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| SCHEMBL11919358 | 0.82 | NFE2L2 (0.45) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| SCHEMBL3058108 | 0.81 | CTNNB1 (0.45) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| SCHEMBL1570557 | 0.81 | CTNNB1 (0.45) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| Hydrochloric Acid SCHEMBL3058112 | 0.81 | KDM4E (0.53) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| SCHEMBL11920844 | 0.81 | CTNNB1 (0.51) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A | |
| SCHEMBL2346222 | 0.81 | L3MBTL1 (0.55) | NFE2L2HCRTR1HCRTR2CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109671-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12448352-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4471034-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLE METHYL KETONE DERIVATIVE AND APPLICATION THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2024-12-04 | — | — | EP | disclosed |
| CN-118556061-A | Disubstituted octahydropyrrolo [3,4-c ] pyrrole methyl ketone derivative and application thereof | 江苏恩华药业股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024109672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLE METHYL KETONE DERIVATIVE AND APPLICATION THEREOF | 江苏恩华药业股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-116056576-A | Use of strobilurin type compounds for combating phytopathogenic fungi containing F129L amino acid substitutions conferring tolerance to Qo inhibitor VIII in mitochondrial cytochrome b proteins | 巴斯夫欧洲公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3946329-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | Curasen Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-114007615-A | Beta adrenergic agonists and methods of use thereof | 库拉森疗法公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2006042289-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1644372-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1625119-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2006-02-15 | — | — | EP | disclosed |
| EP-1597261-A1 | SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| WO-2005087227-A1 | ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004099177-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004074290-A1 | SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448352-B2 | Beta adrenergic agonist and methods of using the same | ADRA2B, ADRB2, ADRB1 | NFE2L2 2763/4885HCRTR1 460/4885HCRTR2 445/4885 |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | TRPV1, CNR2, NTRK1 | NFE2L2 3640/4885HCRTR1 909/4885HCRTR2 591/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | NFE2L2 3204/4885HCRTR1 618/4885HCRTR2 367/4885 |
| US-20260109671-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | NFE2L2 2165/4885HCRTR1 138/4885HCRTR2 55/4885 |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRA2B, ADRB2, ADRB1 | NFE2L2 2763/4885HCRTR1 460/4885HCRTR2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.